About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373

Enveric Biosciences, Inc. (NASDAQ: ENVB) is engaged as a biotechnology company, which focused on the research and development of innovative small-molecule therapies for the treatment of anxiety, depression and addiction disorders. Shares of the biotech company are skyrocketing 90% through early trading on Thursday, May 18, 2023. Over the past three months, Enveric Biosciences has seen average daily volume of 32,720 shares. However, volume of 20.25 million shares or dollar volume of around 49.21 million, has already exchanged hands through early trading.

Shares of Enveric Biosciences are soaring after the company announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) in recognition of their patent application for EB-373, a psilocin prodrug and the company’s lead clinical candidate. This promising compound, designed to treat anxiety disorders, is a part of the family of C4-Carbonothioate-Substituted Tryptamine Derivatives outlined in the pending patent.

The USPTO grants a Notice of Allowance when it concludes that an invention should be patented. The patent, specifically covering EB-373 and other novel prodrugs of psilocin, is a crucial component of the intellectual property associated with Enveric’s new chemical entity (NCE). Notably, Enveric’s forthcoming patent includes composition of matter claims for these innovative compounds.

In addition to this patent, Enveric has submitted other composition of matter patent applications to the USPTO, including those detailing psilocin prodrugs with a crystalline molecular structure. Furthermore, the company has lodged Patent Cooperation Treaty (PCT) and non-US national patent applications to secure worldwide intellectual property rights for their EVM201 and EVM301 Series in specific market countries. Encouragingly, a majority of these applications have received positive International Search Reports (ISR) under the PCT.

Enveric’s CEO, Joseph Tucker, Ph.D., underscores the importance of the USPTO’s positive decision, which brings to light the innovative design and potential benefits of their psilocin prodrugs, specifically the EVM201 Series. The unique design characteristics of these compounds are projected to yield a quicker therapeutic effect, improved control of the treatment response, and fewer gastrointestinal side effects compared to traditional psilocin prodrugs, like psilocybin. For Enveric, establishing robust, multi-layered intellectual property rights around their NCE prodrugs is a key strategic priority as they aim to build a portfolio of novel small-molecule treatments for mental health disorders.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373 appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.